
Oppenheimer Initiates Coverage On Xeris Biopharma Holdings with Outperform Rating, Announces Price Target of $5
Oppenheimer analyst Leland Gershell initiates coverage on Xeris Biopharma Holdings (NASDAQ:XERS) with a Outperform rating and announces Price Target of $5.
